Actinium Pharmaceuticals’ (ATNM) Buy Rating Reiterated at HC Wainwright

Actinium Pharmaceuticals (NYSE:ATNM)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $4.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 142.42% from the company’s current price.

Separately, Wall Street Zen downgraded Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, May 12th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $4.00.

Actinium Pharmaceuticals Stock Performance

Shares of NYSE:ATNM opened at $1.65 on Tuesday. The firm’s 50 day simple moving average is $1.54 and its 200-day simple moving average is $1.36. Actinium Pharmaceuticals has a one year low of $1.03 and a one year high of $8.64. The firm has a market cap of $51.47 million, a PE ratio of -1.19 and a beta of -0.27.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ATNM. AQR Capital Management LLC raised its holdings in shares of Actinium Pharmaceuticals by 278.6% in the 1st quarter. AQR Capital Management LLC now owns 63,249 shares of the company’s stock valued at $102,000 after purchasing an additional 46,545 shares in the last quarter. Callan Family Office LLC purchased a new position in Actinium Pharmaceuticals during the first quarter valued at approximately $38,000. Nuveen LLC bought a new position in Actinium Pharmaceuticals in the first quarter worth approximately $239,000. Invesco Ltd. lifted its holdings in Actinium Pharmaceuticals by 1,135.9% during the first quarter. Invesco Ltd. now owns 153,555 shares of the company’s stock worth $247,000 after buying an additional 141,130 shares during the period. Finally, Gagnon Securities LLC purchased a new stake in Actinium Pharmaceuticals during the first quarter worth $365,000. 27.50% of the stock is currently owned by institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).